Arrowhead Pharmaceuticals Reports $132.7 Million Net Loss and Revenue Decline in Latest Quarter

Arrowhead Pharmaceuticals, Inc. reported significant financial changes in its latest 10-Q filing for the quarter ending March 31, 2026. The company generated revenue of $73.7 million for the three months ended March 31, 2026, a substantial decrease from $542.7 million in the same period last year. For the six months, revenue totaled $337.8 million, down from $545.2 million. The decline in revenue was primarily attributed to reduced contributions from the Sarepta collaboration agreement, although this was partially offset by increased revenue from Novartis and Sanofi.

Operating expenses for Arrowhead increased significantly, totaling $215.0 million for the quarter, compared to $161.5 million in the prior year. Research and development expenses rose to $173.3 million, up from $133.1 million, reflecting the company's ongoing investment in its clinical pipeline. Selling, general, and administrative expenses also increased to $41.7 million from $28.4 million, driven by higher headcount and commercialization efforts related to the launch of REDEMPLO, its FDA-approved treatment for familial chylomicronemia syndrome.

The company reported a net loss of $132.7 million for the quarter, compared to a net income of $370.4 million in the same period last year. This resulted in a net loss per share of $0.93, a stark contrast to the earnings of $2.75 per share reported in the previous year. The significant shift to a net loss was largely due to the sharp decline in revenue and increased operational costs associated with expanding its clinical programs.

In terms of strategic developments, Arrowhead has made notable progress in its clinical pipeline, including the initiation of a Phase 1/2a trial for ARO-DIMER-PA, a dual-target RNAi therapeutic. The company also completed a successful offering of convertible senior notes and common stock, raising approximately $930 million to strengthen its balance sheet. Additionally, Arrowhead entered into a licensing agreement with Madrigal Pharmaceuticals, which includes an upfront payment of $25 million and potential milestone payments totaling up to $975 million.

Looking ahead, Arrowhead maintains a positive outlook, with expectations of sufficient liquidity to fund operations through at least the next twelve months. The company continues to focus on advancing its pipeline of RNAi therapeutics and is preparing for the commercial launch of REDEMPLO in various markets, including Greater China, where it has received regulatory approval. The company is also anticipating further milestone payments from its collaborations, which could enhance its financial position in the coming quarters.